Abstract
Israel was one of the first countries to administer mass vaccination. Consequently, it was among the first countries to experience significant breakthrough infections due to the waning of vaccine-induced immunity, which led to a resurgence of the epidemic. To mitigate the outbreak, Israel launched a pioneering booster campaign. Israel’s success in curtailing the Delta resurgence while imposing only mild non-pharmaceutical interventions has been instrumental in influencing the decision of many countries to initiate a booster campaign. By constructing a detailed mathematical model and calibrating it to the Israeli data, we expand our understanding of the impact of the booster campaign from the individual to the population level. We use the calibrated model to explore counterfactual scenarios in which the booster vaccination campaign is altered and to assess the direct and indirect effects in the different scenarios. Our results point to the vast benefits of vaccinating younger age groups that are not at a high risk of developing severe disease but play an important role in transmission. We further show that when the epidemic is exponentially growing the success of the booster campaign is highly sensitive to the timing of its initiation. Hence a rapid response is an important factor in reducing disease burden using booster vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research of N.G. and R.Y. was supported by the ISRAEL SCIENCE FOUNDATION (grant No. 3730/20) within the KillCorona - Curbing Coronavirus Research Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board of the Sheba Medical Center. Helsinki approval number: SMC-8228-21.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data and source codes used in this study are avaliable online at https://github.com/NGavish/boosterVaccinationModel.git
